financetom
Business
financetom
/
Business
/
Kimmeridge to reduce stake in Commonwealth LNG after financial go-ahead, says CEO
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Kimmeridge to reduce stake in Commonwealth LNG after financial go-ahead, says CEO
Sep 20, 2024 7:28 AM

*

Financial firm acquired Louisiana LNG project owner in

June

Commonwealth LNG to seek financial go-ahead in late 2025

By Curtis Williams

HOUSTON, Sept 20 (Reuters) - Energy investment firm

Kimmeridge Energy Management plans to sell up to 49% of its

stake in a Louisiana liquefied natural gas export project after

it reaches a final investment decision next year, Managing

Partner Ben Dell told Reuters.

In June, Kimmeridge acquired for an undisclosed amount

Commonwealth LNG, which is developing a 9.5 million metric tons

per annum (MTPA) LNG plant in Cameron, Louisiana. The project

has applied for but not received a needed export license from

the Department of Energy.

"Our expectation is under financing we will drop down to

around 51%" stake in Commonwealth LNG, Dell said late Thursday

on the sidelines of the Gastech energy conference.

President Joe Biden administration's LNG export-permit

review pause could be over early next year, he said, projecting

a financial investment decision (FID) could follow in the fourth

quarter of 2025.

"My personal view is the inside date we can FID is late May,

the outside date is October depending on what the DOE does and

what they require," Dell told Reuters.

Kimmeridge plans to invest $1 billion of its own money into

financing the project and has most of the debt and equity

partners ready to go once the project gets permitted, Dell said.

Commonwealth LNG aims to market eight of the plant's 9.5

MTPA production capacity and retain the remainder for its owners

to trade, he said.

Some of the cash to pay for the plant investment will come

from Kimmeridge's natural gas production business that Dell said

is generating $400 million to $500 million in earnings before

interest taxes depreciation and amortization (EBITDA).

"I would like to see us involved in more than one LNG

facility and we will evaluate the shipping, regas and further

downstream to see if we want to participate in that," Dell said.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Update: JPMorgan to Leave Net-Zero Banking Alliance
Update: JPMorgan to Leave Net-Zero Banking Alliance
Jan 7, 2025
10:35 AM EST, 01/07/2025 (MT Newswires) -- (Updates throughout with JPMorgan's ( JPM ) comments.) JPMorgan ( JPM ) is leaving climate group Net-Zero Banking Alliance, a company spokesperson told MT Newswires Tuesday. We will continue to work independently to advance the interests of our firm, our shareholders and our clients and remain focused on pragmatic solutions to help further...
Rezolute Says it Gets Breakthrough Therapy Designation From US FDA for Ersodetug to Treat Hypoglycemia
Rezolute Says it Gets Breakthrough Therapy Designation From US FDA for Ersodetug to Treat Hypoglycemia
Jan 7, 2025
10:34 AM EST, 01/07/2025 (MT Newswires) -- Rezolute ( RZLT ) said Tuesday it has received the US Food and Drug Administration's Breakthrough Therapy designation for its ersodetug monoclonal antibody to treat hypoglycemia due to congenital hyperinsulinism. The regulator's decision was based on the company's phase 2b trial of ersodetug in patients with congenital hyperinsulinism, which safely showed significant improvements...
Actuate Therapeutics Gets Orphan Medicinal Product Label for Elraglusib in EU
Actuate Therapeutics Gets Orphan Medicinal Product Label for Elraglusib in EU
Jan 7, 2025
10:34 AM EST, 01/07/2025 (MT Newswires) -- Actuate Therapeutics ( ACTU ) said Tuesday that the European Medicines Agency has granted orphan medicinal product designation to elraglusib for the treatment of pancreatic ductal adenocarcinoma. The company said the designation is granted to therapies intended for the treatment of life-threatening diseases that affect no more than two in 10,000 people in...
NEO Battery Materials Launches New Product Line With
NEO Battery Materials Launches New Product Line With "Breakthrough" Battery Capacity
Jan 7, 2025
10:30 AM EST, 01/07/2025 (MT Newswires) -- NEO Battery Materials ( NBMFF ) on Tuesday announced the launch of an advanced high-performance silicon anode product with breakthrough battery capacity. The NBMSiDE P-300 product line showed a 43% to 130% improvement in initial battery capacity over traditional graphite anodes with less material used, the company said. NEO, which has submitted a...
Copyright 2023-2026 - www.financetom.com All Rights Reserved